Rho kinase, a promising drug target for neurological disorders

By B. Mueller, H. Mack, N. Teusch. Nature reviews. Drug discovery, 2005

597 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Therapeutic interventions after spinal cord injury (2006, background): “Rho kinase (ROCK) acts as a downstream effector of Rh”
Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity (2010, methodology): “To elucidate the physiological roles of Rho-kinase, small molecule inhibitors have been developed and investigated in various cell types and animal models [Mueller et al., 2005; Shimokawa and Rashid, 2007].”
GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo (2007, methodology): “(52–54) One of the Rock inhibitors, fasudil (also known as HA-1077 and AT877), is already being used for the treatment of patients with cardiovascular disorders.(55)”
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms (2005, background): “The observation that statin-mediated inhibition of Rho is mechanistically important for their anti-inflammatory effects in cell culture has prompted studies of the development of direct Rho kinase inhibitor”